ANIKA THERAPEUTICS INC (ANIK) Stock Price & Overview

NASDAQ:ANIK • US0352551081

Current stock price

14.2 USD
-0.1 (-0.7%)
At close:
14.2 USD
0 (0%)
After Hours:

The current stock price of ANIK is 14.2 USD. Today ANIK is down by -0.7%. In the past month the price increased by 41.15%. In the past year, price decreased by -10.75%.

ANIK Key Statistics

52-Week Range7.8701 - 16.695
Current ANIK stock price positioned within its 52-week range.
1-Month Range9.8784 - 15.061
Current ANIK stock price positioned within its 1-month range.
Market Cap
204.764M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.76
Dividend Yield
N/A

ANIK Stock Performance

Today
-0.7%
1 Week
+0.57%
1 Month
+41.15%
3 Months
+48.54%
Longer-term
6 Months +63.78%
1 Year -10.75%
2 Years -44.09%
3 Years -50.56%
5 Years -65.19%
10 Years -68.25%

ANIK Stock Chart

ANIKA THERAPEUTICS INC / ANIK Daily stock chart

ANIK Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ANIK. When comparing the yearly performance of all stocks, ANIK is one of the better performing stocks in the market, outperforming 82.13% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ANIK Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ANIK. No worries on liquidiy or solvency for ANIK as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ANIK Earnings

On February 26, 2026 ANIK reported an EPS of 0.02 and a revenue of 30.61M. The company beat EPS expectations (109.12% surprise) and beat revenue expectations (3.95% surprise).

Next Earnings DateMay 7, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$0.02
Revenue Reported30.615M
EPS Surprise 109.12%
Revenue Surprise 3.95%

ANIK Forecast & Estimates

8 analysts have analysed ANIK and the average price target is 16.32 USD. This implies a price increase of 14.93% is expected in the next year compared to the current price of 14.2.

For the next year, analysts expect an EPS growth of 50.34% and a revenue growth 5.57% for ANIK


Analysts
Analysts85
Price Target16.32 (14.93%)
EPS Next Y50.34%
Revenue Next Year5.57%

ANIK Groups

Sector & Classification

ANIK Financial Highlights

Over the last trailing twelve months ANIK reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 63.29% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-33.04M
Industry RankSector Rank
PM (TTM) N/A
ROA -17.44%
ROE -22.5%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%101.33%
Sales Q2Q%0.04%
EPS 1Y (TTM)63.29%
Revenue 1Y (TTM)N/A

ANIK Ownership

Ownership
Inst Owners86.01%
Shares14.42M
Float13.80M
Ins Owners3.88%
Short Float %5.54%
Short Ratio4.92

ANIK Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.8398.492B
AMGN AMGEN INC16.04198.265B
GILD GILEAD SCIENCES INC16.4180.267B
VRTX VERTEX PHARMACEUTICALS INC24.21121.459B
REGN REGENERON PHARMACEUTICALS15.9578.932B
ALNY ALNYLAM PHARMACEUTICALS INC42.0142.071B
INSM INSMED INC N/A30.073B
BIIB BIOGEN INC11.2927.136B
NTRA NATERA INC N/A26.973B
UTHR UNITED THERAPEUTICS CORP17.9523.353B
MRNA MODERNA INC N/A21.086B
EXAS EXACT SCIENCES CORP340.7419.713B
RVMD REVOLUTION MEDICINES INC N/A18.84B

About ANIK

Company Profile

ANIK logo image Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

Company Info

IPO: 1985-05-16

ANIKA THERAPEUTICS INC

32 Wiggins Ave

Bedford MASSACHUSETTS 01730 US

CEO: Cheryl R. Blanchard

Employees: 288

ANIK Company Website

ANIK Investor Relations

Phone: 17814579000

ANIKA THERAPEUTICS INC / ANIK FAQ

What does ANIK do?

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.


What is the stock price of ANIKA THERAPEUTICS INC today?

The current stock price of ANIK is 14.2 USD. The price decreased by -0.7% in the last trading session.


What is the dividend status of ANIKA THERAPEUTICS INC?

ANIK does not pay a dividend.


What is the ChartMill technical and fundamental rating of ANIK stock?

ANIK has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the PE ratio for ANIK stock?

ANIKA THERAPEUTICS INC (ANIK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.76).


Should I buy ANIK stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ANIK.


How many employees does ANIKA THERAPEUTICS INC have?

ANIKA THERAPEUTICS INC (ANIK) currently has 288 employees.